LMR Partners LLP reduced its position in Zoetis Inc. (NYSE:ZTS) by 43.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 20,189 shares of the company’s stock after selling 15,521 shares during the quarter. LMR Partners LLP’s holdings in Zoetis were worth $1,287,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. increased its holdings in Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after purchasing an additional 230 shares in the last quarter. Harfst & Associates Inc. increased its holdings in Zoetis by 16.1% in the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after purchasing an additional 260 shares in the last quarter. Almanack Investment Partners LLC. acquired a new stake in Zoetis in the 2nd quarter valued at $119,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in Zoetis by 251.9% in the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after purchasing an additional 1,360 shares in the last quarter. Finally, Peddock Capital Advisors LLC acquired a new stake in Zoetis in the 2nd quarter valued at $140,000. 93.37% of the stock is currently owned by institutional investors and hedge funds.

Shares of Zoetis Inc. (NYSE ZTS) traded up $0.22 during trading on Friday, hitting $71.29. The stock had a trading volume of 1,200,253 shares, compared to its average volume of 2,918,628. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45. The firm has a market capitalization of $34,631.58, a P/E ratio of 32.60, a PEG ratio of 2.09 and a beta of 1.02. Zoetis Inc. has a 12 month low of $48.55 and a 12 month high of $72.14.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.02. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The company’s revenue was up 8.5% on a year-over-year basis. During the same period last year, the firm earned $0.52 earnings per share. sell-side analysts expect that Zoetis Inc. will post 2.37 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Thursday, November 9th will be paid a dividend of $0.105 per share. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $0.42 annualized dividend and a dividend yield of 0.59%. Zoetis’s dividend payout ratio is presently 22.11%.

Several brokerages recently issued reports on ZTS. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a report on Thursday, October 12th. Cantor Fitzgerald reiterated a “buy” rating and issued a $75.00 price target on shares of Zoetis in a report on Wednesday, September 6th. BidaskClub downgraded Zoetis from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Morgan Stanley increased their price target on Zoetis from $61.00 to $70.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Finally, Goldman Sachs Group Inc reiterated a “neutral” rating and issued a $62.00 price target on shares of Zoetis in a report on Monday, August 7th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $67.65.

WARNING: “LMR Partners LLP Cuts Position in Zoetis Inc. (ZTS)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.watchlistnews.com/lmr-partners-llp-cuts-position-in-zoetis-inc-zts/1726130.html.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.